Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 30;12:651403. doi: 10.3389/fmicb.2021.651403

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Shionoya, Yamasaki, Iwanami, Ito, Fukushi, Ohashi, Saso, Tanaka, Aoki, Kuramochi, Iwami, Takahashi, Suzuki, Muramatsu, Takeda, Wakita and Watashi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Prediction of the impact of MFQ and HCQ treatment on SARS-CoV-2 dynamics in clinical settings. (A,B) The predicted viral load dynamics without (A, black), upon MFQ (1,000 mg oral, once) (A, red) or upon HCQ (400 mg oral, once per day) (A, blue) administration and the time-dependent antiviral activity of MFQ and HCQ (B) predicted by pharmacokinetics/pharmacodynamics/viral-dynamics (PK/PD/VD) models. (C,D) The cumulative viral load calculated as the area under the curve in (A) and the duration of virus shedding (days) [time from symptom onset to the day achieving a viral load under the detection limit (black horizontal line) in (A)] were evaluated for non-treatment (black), MFQ treatment (red) or HCQ treatment (blue).